The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
== Interactions == Pindolol has been found to robustly potentiate the effects of the serotonergic psychedelic dimethyltryptamine (DMT). This is thought to be due to its serotonin 5-HT1A receptor antagonism, which is thought to disinhibit the effects of DMT.
=== Juvenile idiopathic arthritis === Adalimumab has been shown to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children aged four years and older.
In addition, the Times reported that Vice President-elect JD Vance had led a group of Republicans, including Donald Trump Jr., former Trump aide Steve Bannon, political activist Charlie Kirk, and Breitbart News reporter Matt Boyle, to support Hegseth's nomination. Trump allies took a direct approach to addressing the controversies, including an interview with Megyn Kelly that impressed Trump. Hegseth appeared at the United States Capitol in December; Trump publicly reaffirmed his support for Hegseth afterwards. The visit gave Iowa senator Joni Ernst, who had threatened his nomination, a positive impression of Hegseth. Hegseth appeared before the Senate Committee on Armed Services on January 14. He positioned himself as a "warrior" while denying the allegations and his previous claims that women should not serve in combat roles. Hegseth was criticized by Democrats over allegations of sexual misconduct, financial mismanagement, and alcohol issues. Rhode Island senator Jack Reed, the committee's ranking member, noted that Hegseth had used the term "jagoff" in his book The War on Warriors (2024) to derogatorily refer to a Judge Advocate General officer who reprimanded him on the use of rocket-propelled grenades. He did not answer a question from Virginia senator Tim Kaine on whether or not sexual assault, drinking, or infidelity were disqualifying. The Committee on Armed Services voted to advance his nomination 14–13 along party lines on January 20, after Trump was inaugurated.
Sources: en.wikipedia.org
"Exporting pine nuts to Europe". Center for the Promotion of Imports. 24 April 2019. Archived from the original on 3 January 2023. Retrieved 3 January 2023. Charles, Dan (8 October 2014). "Love Pine Nuts? Then Protect Pine Forests". NPR. Retrieved 19 April 2015.
Biological and biotechnical rejuvenation-related results A new cellular rejuvenation therapy of bursts of iPSC reprogramming is reported, which can reverse aspects of aging in mice, without causing cancer or other health problems. Bioresearchers demonstrate an in vitro method (MPTR) for rejuvenation (including the transcriptome and epigenome) reprogramming, working better than previous reprogramming methods, in which fibroblast skin cells temporarily lose their cell identity. Scientists report the key molecular mechanisms of rejuvenation they found in a comparison of the newly presented genomes of the biologically immortal T. dohrnii and a similar but non-rejuvenating jellyfish, involving e.g. DNA replication and repair, and stem cell renewal. A first spatiotemporal map reveals key insights about axolotl brain regeneration. Axolotls retain regenerative capacity in their aging throughout their lives. It is thought that by "understanding the mechanisms of regeneration, we eventually will be able to enhance our intrinsic regenerative abilities in order to slow and even reverse the damage of aging." Scientists report leprosy-causing bacteria viably regenerate and rejuvenate the liver in its armadillos hosts, which may enable novel human therapies. A study shows that infusing the nourishing cerebrospinal fluid from around brain cells of young mice into aged brains rejuvenates aspects of the brain, identifying FGF17 as a key target for potential therapeutics such as of anti-aging.
=== Daria Greenock === Daria Greenock (Freya Mavor) is a VP at Pierpoint's CPS desk, and Harper's line manager during her internship. Daria works to foster a poised, professional relationship with Harper, who nonetheless finds herself drawn more to Eric's fiery, cutthroat management style, frequently undercutting Daria in the process. When Harper confides to Daria that Eric locked her in a conference room to berate her for a mistake, Daria tells Sara and the two push Harper to file a formal complaint, getting Eric fired and positioning Daria to become CPS' managing director in his place. Harper is initially allowed to keep the outsize bonus that Eric paid her as long as she keeps it quiet, but Daria later has Harper pay it back after Harper talks about it during a party. On RIF day, Harper accepts a deal to retract her complaint against Eric and get him rehired, leading to Daria's firing. In series 2, Daria is revealed to have joined Goldman Sachs; though she is on maternity leave, she visits the office during a sham interview with Harper, Eric, and Rishi to revel in their humiliation. In series 3, however, Daria agrees to help Harper short Pierpoint alongside Kenny and Jackie, who have also joined Goldman Sachs, out of spite towards their ex-employer.
=== Shape === The shape of the bottle is related to both ease of use and ease of cleaning (see History). Designers sometimes suggest that naturalistic designs will mean that babies can transition between breast or bottle without issues. Other bottles have been invented with unique shapes designed to speed up the warming and cooling of breast milk, saving time, reducing bacterial growth, and reducing exposure to temperatures that can damage the nutrients in breast milk. "Anti-colic" bottles have been put forward with the goal of reducing "gassiness" and distress when feeding. Designs often seek to minimize the sucking in of air by the baby while feeding. Some bottles try to minimize the mixing of air into the milk within the bottle. At the same time, it is desirable to avoid creating an internal vacuum as the infant sucks out fluids, since this will make it harder to feed. Designs may rely on the bottle's shape or incorporate different types of "venting".
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.